OOIR: Observatory of International Research

Papers

(The H4-Index of Frontiers in Oncology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future	240
EMT Factors and Metabolic Pathways in Cancer	198
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers	191
Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond	168
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics	164
Mechanisms of Cancer Resistance to Immunotherapy	156
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression	156
Chronic Stress Promotes Cancer Development	155
The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity	153
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy	150
Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers	144
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology	144
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways	135
Integrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools	133
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?	128
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions	127
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors	124
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis	121
Breast Cancer Survivorship, Quality of Life, and Late Toxicities	119
Boron Neutron Capture Therapy: A Review of Clinical Applications	118
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy	117
Mutant p53 in Cancer Progression and Targeted Therapies	117
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis	116
The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy	114
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches	113

Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming	113
Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma	113
Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors	111
Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups	111
Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data	107
Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment	106
P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers	100
Metabolic Adaptations in Cancer Stem Cells	99
Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship	98
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy	98
Artificial Convolutional Neural Network in Object Detection and Semantic Segmentation for Medical Imaging Analysis	98
Integrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma	95
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells	95
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer	94
Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma	93
Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib	92
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects	92
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade	91
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies	91
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model	91
Delivery and Biosafety of Oncolytic Virotherapy	88
An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes	88
Has COVID-19 Affected Cancer Screening Programs? A Systematic Review	88
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment	88
Proline Metabolism in Tumor Growth and Metastatic Progression	88
Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic	87
Sexual Dimorphism in Colon Cancer	86
Shaping Up the Tumor Microenvironment With Cellular Fibronectin	86
A Review on Anti-Tumor Mechanisms of Coumarins	86
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism	85
Ferroptosis in Cancer Treatment: Another Way to Rome	85
Obesity, Type 2 Diabetes, and Cancer Risk	85
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma	83
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy	83
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?	83
The Role of the Transcription Factor EGR1 in Cancer	83
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy	83
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients	83
Emerging Roles of Wnt Ligands in Human Colorectal Cancer	82
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation	81
Knowledge Domain and Emerging Trends in Ferroptosis Research: A Bibliometric and Knowledge-Map Analysis	80
BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining	79
Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study	79
New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma	79
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies	79
A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients	77
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review	77
Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases	77
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion	77
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease	77

The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy	76
Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications	76
Role of DNA Methylation in the Resistance to Therapy in Solid Tumors	76